Erythropoietin should be part of congestive heart failure management

被引:40
作者
Silverberg, DS
Wexler, D
Blum, M
Schwartz, D
Wollman, Y
Iaina, A
机构
[1] Tel Aviv Med Ctr & Sch Med, Dept Nephrol, IL-64239 Tel Aviv, Israel
[2] Tel Aviv Med Ctr & Sch Med, Dept Cardiol, Tel Aviv, Israel
[3] Tel Aviv Med Ctr & Sch Med, Congest Heart Failure Clin, Tel Aviv, Israel
关键词
erythropoietin; iron; congestive heart failure; chronic renal insufficiency; anemia;
D O I
10.1046/j.1523-1755.64.s87.7.x
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Background. Up to 64% of patients referred to nephrologists with chronic kidney insufficiency (CKI) have evidence of congestive heart failure (CHF), and most of these patients are also anemic. We have called this triad of anemia, CKI, and CHF the cardio renal anemia (CRA) syndrome. The 3 components of this syndrome form a vicious circle, with each one capable of causing or worsening the other 2. Anemia is found in one-third to one-half of CHF patients and can either cause or worsen the CHF, and can increase the mortality, hospitalization, and malnutrition in this condition. Anemia is also associated with a worsening of renal function in CHF and CKI, causing a more rapid progression to dialysis than is found in those without anemia. Uncontrolled CHF can cause rapid deterioration of renal function and may also cause anemia. Chronic kidney insufficiency can cause anemia and worsen the CHF. Methods. Aggressive therapy of CHF with all the accepted CHF medications in the accepted doses will often fail to improve the CHF if anemia is also present but is not corrected. However, when the anemia was corrected with subcutaneous erythropoietin and, in some cases, with intravenous iron, the cardiac and patient function and quality of life improved, the need for hospitalization and for high-dose oral and intravenous diuretics was strikingly reduced, and renal function, which had previously been deteriorating, stabilized. Results. Nephrologists should carefully assess the cardiac status of all CKI patients, including routinely getting an echocardiogram and possibly measuring B-type natriuretic peptide. Where CHF is present, the indicated CHF agents in the indicated doses should be used. Conclusion. Studies show that most cardiologists and internists do not recognize, investigate, or treat the anemia frequently seen in their CHF patients. In our experience cooperation between nephrologists and these specialists has increased their awareness about anemia, resulting in its earlier correction, and thus preventing the deterioration of the CHF, the CKI, and the anemia itself.
引用
收藏
页码:S40 / S47
页数:8
相关论文
共 73 条
[1]   Reduced kidney function and anemia as risk factors for mortality in patients with left ventricular dysfunction [J].
Al-Ahmad, A ;
Rand, WM ;
Manjunath, G ;
Konstam, MA ;
Salem, DN ;
Levey, AS ;
Sarnak, MJ .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2001, 38 (04) :955-962
[2]  
Amann K, 2002, CLIN NEPHROL, V58, pS62
[3]  
ANAND IS, 1993, BRIT HEART J, V70, P357
[4]   Hemodilution is common in patients with advanced heart failure [J].
Androne, AS ;
Katz, SD ;
Lund, L ;
LaManca, J ;
Hudaihed, A ;
Hryniewicz, K ;
Mancini, DM .
CIRCULATION, 2003, 107 (02) :226-229
[5]   Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling [J].
Calvillo, L ;
Latini, R ;
Kajstura, J ;
Leri, A ;
Anversa, P ;
Ghezzi, P ;
Salio, M ;
Cerami, A ;
Brines, M .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (08) :4802-4806
[6]   Effect of anaemia and cardiovascular disease on surgical mortality and morbidity [J].
Carson, JL .
LANCET, 1996, 348 (9034) :1055-1060
[7]   Morbidity risk assessment in the surgically anemic patient [J].
Carson, JL .
AMERICAN JOURNAL OF SURGERY, 1995, 170 (6A) :S32-S36
[8]   Carvedilol increases two-year survival in dialysis patients with dilated cardiomyopathy -: A prospective, placebo-controlled trial [J].
Cice, G ;
Ferrara, L ;
D'Andrea, A ;
D'Isa, S ;
Di Benedetto, A ;
Cittadini, A ;
Russo, PE ;
Golino, P ;
Calabrò, R .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (09) :1438-1444
[9]   Management of heart failure in primary care (the IMPROVEMENT of Heart Failure Programme): an international survey [J].
Cleland, JGF ;
Cohen-Solal, A ;
Aguilar, JC ;
Dietz, R ;
Eastaugh, J ;
Follath, F ;
Freemantle, N ;
Gavazzi, A ;
van Gilst, WH ;
Hobbs, FDR ;
Korewicki, J ;
Madeira, HC ;
Preda, I ;
Swedberg, K ;
Widimsky, J .
LANCET, 2002, 360 (9346) :1631-1639
[10]   The EuroHeart Failure survey programme - a survey on the quality of care among patients with heart failure in Europe - Part 1: patient characteristics and diagnosis [J].
Cleland, JGF ;
Swedberg, K ;
Follath, F ;
Komajda, M ;
Cohen-Solal, A ;
Aguilar, JC ;
Dietz, R ;
Gavazzi, A ;
Hobbs, R ;
Korewicki, J ;
Madeira, HC ;
Moiseyev, VS ;
Preda, I ;
van Gilst, WH ;
Widimsky, J ;
Freemantle, N ;
Eastaugh, J ;
Mason, J .
EUROPEAN HEART JOURNAL, 2003, 24 (05) :442-463